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Abstract: Pin1 is a peptidyl-prolyl isomerase that catalyzes the cis/trans conversion of 
phosphorylated proteins at serine or threonine residues which precede a proline. The peptidyl-prolyl 
isomerization induces a conformational change of the proteins involved in cell signaling process. 
Pin1 dysregulation has been associated with some neurodegenerative disorders such as Alzheimer’s 
disease, Parkinson’s disease and Huntington’s disease. Proline-directed phosphorylation is a common 
regulator of these pathologies and a recent work showed that it is also involved in prion disorders. In 
fact, prion protein phosphorylation at the Ser-43-Pro motif induces prion protein conversion into a 
disease-associated form. Furthermore, phosphorylation at Ser-43-Pro has been observed to increase 
in the cerebral spinal fluid of sporadic Creutzfeldt-Jakob Disease patients. These findings provide 
new insights into the pathogenesis of prion disorders, suggesting Pin1 as a potential new player in 
the disease. In this paper, we review the mechanisms underlying Pin1 involvement in the 
aforementioned neurodegenerative pathologies focusing on the potential role of Pin1 in prion 
disorders. 
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1. Introduction 
Proline-directed protein phosphorylation is a key event in the regulation of cell signaling that 
has gained attention thanks to the recent discovery of Pin1, a member of the peptidyl-prolyl cis/trans 
isomerase (PPIase) family. Pin1 controls the cis/trans isomerization of protein phosphorylated at 
specific serine or threonine residues preceding a proline (pSer/Thr-Pro), participating in the 
regulation of their functions [1, 2].  
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A deregulation of proline-directed protein phosphorylation has been associated to an alteration 
of vital cellular functions in several neurodegenerative disorders [3, 4]. In Alzheimer’s disease (AD), 
aberrant amyloid precursor protein (APP) and tau phosphorylation occurs, leading to extracellular 
amyloid plaques and intracellular neurofibrillary tangles (NFTs) formation made of toxic 
amyloid-beta peptides and hyperphosphorylated tau, respectively. The accumulation of these deposits 
causes synaptic dysfunction and loss of neurons [5]. Moreover, α-synuclein (α-syn) phosphorylation 
is altered in Parkinson’s disease (PD) resulting in insoluble and fibrillar α-syn inclusions that cause 
neuronal death [6]. A recent paper showed the effect of phosphorylation on protein misfolding, 
confirming the influence of this mechanism in triggering protein aggregation and amyloid formation [7]. 
Also in Huntington’s disease (HD), proline-directed protein phosphorylation plays a crucial role in 
determining neuronal apoptosis by acting on p53 tumor suppressor gene [8].  
Several papers suggest a key role for Pin1 in the pathogenesis of these diseases, although the 
detailed molecular mechanism is not yet well understood [9, 10]. So far, Pin1 involvement in AD has 
been the most extensively investigated. Indeed, decreased Pin1 levels were observed in the brain of 
AD patients resulting in the accumulation of cis tau at the early stage of the disease, as recently 
revealed by the development of antibodies specific for cis and trans isomers of pThr231-Pro motif in 
tau [11].  
Besides the role of proline-directed protein phosphorylation on tau, APP, α-syn, and p53, a 
recent finding supports the possibility that phosphorylation could represent a physiological 
mechanism of prion protein conversion. Indeed, phosphorylation of prion protein at Ser-43-Pro 
induces the formation of proteinase K resistant aggregates in vivo [12]. This result suggests that Pin1 
could have a crucial function not only in AD, PD, and HD, but also in prion disorders. However, this 
hypothesis requires further investigation. In this article, we review Pin1 involvement in 
neurodegenerative pathologies focusing on the potential impact of this PPIase in the development of 
prion disorders.  
2. Pin1 structure and function 
Pin1 was identified in 1996 by Lu and colleagues as a protein interacting with NIMA, a mitotic 
kinase involved in cancer [1]. The discovery revealed the ability of Pin1 to suppress NIMA activity and 
brought attention to this new mitotic regulator enzyme able to conformationally modify phosphorylated 
proteins into different foldings. This molecular switch is commonly known as cis/trans isomerization, 
an important mechanism that determines the fate of phosphoproteins [13]. Moreover, transition from 
cis to trans or vice versa depends on the structure of the target protein [10]. 
Pin1 catalyzes conformational changes of specific pSer/Thr-Pro motifs that are phosphorylated 
by so called “proline-directed protein kinases,” such as mitogen-activated protein kinases (MAP 
kinases), glycogen synthase kinase-3 (GSK-3), and cyclin-dependent kinases (CDKs) [10]. 
Pin1-catalyzed isomerization is allowed by the interesting stereochemistry of proline, consisting of a 
5-membered ring on its chain of peptides [10].  
Pin1 is an 18 kDa protein made up of an N-terminal WW domain and a C-terminal catalytic 
domain that are connected by a flexible linker [14]. The WW domain allows Pin1 to bind its 
substrates while the C-terminal domain catalyzes their cis/trans isomerization [2]. This classic 
“tag-and-twist” mechanism has been recently revised by Matena and colleagues. They postulate a 
more complex scenario in which the two domains of Pin1 are not completely independent from one 
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another and suggest transient domain interactions that enhance the affinity of WW domain towards 
phosphorylated substrates [15]. Although the exact catalytic mechanism by which Pin1 accelerates 
the isomerization is still unknown, a recent study has shown how Pin1 is able to reduce the free 
energy barrier for the trans form in order to obtain an almost barrier free reaction. More specifically, 
pThr motif allows substrate anchoring at Pin1, while Cys-113 and Ser-154 residues in the enzyme 
influence the isomerization reaction of the cis and trans forms, respectively [16]. 
Pin1 is differently expressed by mitotic cells and neurons. In the first case, Pin1 levels are associated 
with the cell’s proliferative capacity. While in neurons, Pin1 levels are much higher during developmental 
stages than in the adult, suggesting a role for Pin1 in cortical neuronal differentiation [11]. However, the 
physiological function of prolyl isomerase in neurons is not fully understood. Evidence has shown 
that, thanks to its ubiquitous expression, Pin1 regulates the isomerization of several substrates such 
as c-Jun, NF-κB, p53, beta-catenin, c-Myc, IRAK1, gephyrin, myeloid cell leukemia sequence-1 
(MCL-1), tau, and APP [9, 17 ,18]. Although it is expressed mainly in the nucleus, Pin1 also 
localizes in other subcellular compartments, such as the cytoplasm and mitochondria, depending on 
substrate localization. For instance, it co-localizes with the full length APP protein at the plasma 
membrane, suggesting an involvement of the isomerase in APP turnover [17]. 
3. Misfolded proteins and neurodegeneration 
The accumulation of misfolded and aggregated proteins is a common hallmark of several 
neurodegenerative diseases. Indeed, amyloid plaques and NFTs accumulate in AD, Lewy bodies in 
PD, inclusions containing Htt in HD, and prion plaques in prion disorders [19]. These amyloid-like 
protein deposits are in dynamic equilibrium with the soluble species resulting in variable solubility, 
stability, and size [20]. Contrasting hypotheses have been proposed regarding their neurotoxicity. 
However, current evidence indicates that these insoluble inclusions might exert a neuroprotective 
mechanism by sequestering and isolating toxic misfolded intermediates [21]. Although to date, the 
toxic question remains unresolved, significant efforts are now being made to address another 
important point: the mechanisms governing the formation and propagation of protein aggregates. 
Protein aggregation can be regulated by several cellular events including covalent modifications such 
as nitration, ubiquitination and phosphorylation [22]. Importantly, phosphorylation can affect protein 
conformation, function, as well as localization, and its role in neurodegeneration will be fully 
discussed below.  
Moreover, an emerging hypothesis has tried to explain the propagation of disease-associated 
proteins on the basis of recent findings on the transmission of several amyloidogenic proteins. 
Contrary to the traditional hypothesis supporting cell-autonomous development of protein aggregates, 
a growing number of studies provided convincing evidence of cell-cell propagation of these deposits. 
The proposed mechanism resembles that of the pathogenesis of prion diseases demonstrating a 
common role for prions in neurodegeneration. Thus, a prion-like self-propagating process is shared 
by a wide range of pathological aggregates including Aβ, tau, α-syn, and Htt. Several in vitro and in 
vivo studies showed the transmissibility of non-prion protein deposits, suggesting that they might act 
as “seeds” to initiate aggregate formation by recruiting additional soluble species into elongating 
fibrils [23]. In addition, it has been shown that aggregates can spread, by prion-like mechanism, 
through anatomical connections throughout the brain [24]. To date, it is unclear what determines the 
selective vulnerability of different brain regions. 
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4. Pin1 and AD 
AD is the most common neurodegenerative disorder among people over 65 years old. It is 
characterized by progressive neuronal loss and synaptic dysfunction that lead to cognitive decline 
and changes in mood and personality [25]. Growing evidence supports the concept that AD is a 
multi-factorial disorder, hence several pathogenic factors contribute to the disease [26]. Although, to 
date, AD pathogenesis is not completely clear, the accumulation of intracellular NFTs and 
extracellular amyloid plaques are universally considered the major pathogenic determinants of the 
disease [5]. NFTs are composed of hyperphosphorylated tau, high molecular-weight microtubule 
associated proteins (MAPs), medium and high molecular weight neurofilament proteins (NFM/H), 
and vimentin [27]. On the other hand, amyloid plaques consist of amyloid-beta peptides generated 
from APP processing alteration, resulting in increased amyloidogenic pathway [28]. Tau, NF, and 
APP processing are regulated by phosphorylation under physiological conditions; therefore, a 
dysregulation of this mechanism induces pathogenic proteins generation. Notably, increased 
proline-directed phosphorylation seems to affect tau and NF, as well as APP functioning in AD; 
several works show the involvement of Pin1 in the pathology [3, 17]. Indeed, Pin1 knockout mice 
develop AD-related features such as amyloid and tau pathology together with age-dependent motor 
and behavioral deficits [3, 17, 29]. Moreover, a reduction of Pin1 activity has been observed in 
human brain regions notoriously prone to degenerate in AD [3]. The low amount of Pin1 was not 
only due to decreased protein levels, but also to increased protein oxidation. Importantly, 
Cys-113-oxidized Pin1, a catalytically inactive form, has been found to be significantly increased in 
AD mouse models as well as in human AD brains [30-32].  
Overall, Pin1 reduction greatly affects isomerization of phosphorylated tau, NF, and APP, 
impairing the equilibrium between cis and trans conformations. Consequently, the pathogenic cis 
isomer will be mainly produced, leading to an alteration of tau and APP function, which in turn 
results in the appearance of NFTs and amyloid plaques.  
4.1. Pin1 and tau protein 
Tau is a microtubule-associated protein (MAP) and plays a key role in stabilizing microtubular 
structures essential for connecting the neuronal cell body and synapse. A finely regulated balance 
between phosphorylation and dephosphorylation controls tau binding to microtubules, contributing 
to axonal outgrowth and neuronal plasticity [33]. When this balance is disrupted, tau becomes 
hyperphosphorylated, dissociates from microtubules, and starts to self-aggregate. This forms NFTs 
that destabilize the cytoskeleton, leading to neuronal death [34]. 
Interestingly, tau hyperphosphorylation occurs mostly at Ser/Thr-Pro sites that are targeted by 
protein kinases particularly active in AD such as GSK3β and Cdk5 [35]. Accordingly, AD-related 
Pin1 deficiency inhibits dephosphorylation at Cdk5-mediated sites by protein phosphatase 2A 
(PP2A), which is downregulated in AD [36]. These observations suggest a neuroprotective role of 
Pin1 in AD, which has been further investigated by analyzing the ability of Pin1 to bind 
pSer/Thr-Pro tau.  
The first result revealed the interaction of the isomerase with two tau phosphorylation sites: 
Thr-212 and Thr-231 [37]. In particular, cis pThr-231-Pro tau was observed as the earliest pathogenic 
sign in mild cognitive impairment (MCI) brains, detected by an antibody developed by Nakamura 
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and colleagues. They generated two antibodies that allowed them to discriminate between cis and 
trans pThr-231-Pro tau isomers [11] and, consequently, a specific immunotherapy against cis 
pThr-231-Pro tau has been proposed [38].  
However, only two Pin1 binding sites cannot protect against tau hyperphosphorylation, 
requiring further investigation. Recently, Kimura and colleagues showed that Pin1 binds tau at all 
Cdk5-mediated sites: Ser-202, Thr-205, Ser-235, and Ser-404. Furthermore, the binding was stronger 
to Ser-202 and Thr-205 compared with Ser-235 and Ser-404 [35]. Thus, Pin1 should be able to 
accelerate cis to trans isomerization of the aforementioned phosphorylated sites that would then be 
correctly dephosphorylated by PP2A. However, the analysis of remaining pSer/Thr tau sites would 
be useful to understand Pin1 involvement in AD pathology and to develop a therapeutic strategy to 
restore tau physiological function. 
4.2. Pin1 and NFs 
NFs are the most abundantly expressed cytoskeletal proteins in myelinated axons and consist of 
three different molecular weight subunits (NF-L, NF-M, and NF-H) and α-internexin [39]. The 
carboxy terminal domains of NF-M and NF-H are rich in lysine/serine/proline (KSP) repeats that, 
under normal conditions, are phosphorylated in the axonal compartment. This post translational 
modification allows NFs to contribute to neuronal differentiation, axon outgrowth, regeneration, and 
guidance [40]. In the same manner as tau, NFs became hyperphosphorylated in neuronal cell bodies 
in AD [41] and the aberrant phosphorylation is the result of deregulation of several protein kinases 
and protein phosphatases, such as PP2A. In that respect, Pin1 has been shown to stabilize the 
AD-related stress induced hyperphosphorylation of KSP repeats that are mediated by ERK1/2 and 
JNK. In addition, Pin1 prevents PP2A-mediated NFs dephosphorylation in neurodegeneration, 
promoting the isomerization of phosphorylated NF proteins [4]. 
4.3. Pin1 and APP 
APP is an ubiquitous expressed transmembrane protein that is abundant in neurons and 
regulates nervous system development, especially neuronal growth and survival [42]. Depending on 
its cellular localization, APP undergoes a non-amyloidogenic or amyloidogenic processing. In the 
first case, it is localized to the plasma membrane and cleaved by alpha and gamma secretases that 
prevent amyloid-beta peptide formation. However, when APP is internalized to the endosomes, 
amyloid-beta peptides are generated by beta secretases [43]. The amyloidogenic pathway is increased 
in AD and has been associated with APP phosphorylation of Thr-668-Pro residues motif that 
determines its isomerization from trans to cis [44]. Indeed, while trans conformation slows 
amyloid-beta production, the cis conformation is related to amyloidogenic processing. Normally, 
Pin1 was found to bind pThr-668-Pro, maintaining the balance between the two isomers. But the 
reduction of Pin1 levels and activity observed in AD brains slows the uncatalyzed cis to trans 
isomerization rate, leading to a higher concentration of the cis pThr-668-Pro motif for a longer time 
and promoting amyloid-beta generation [17].  
Recently, another mechanism has been discovered by which Pin1 would be able to indirectly 
regulate APP processing. The new proposed model suggests that Pin1 inhibits GSK3β activity, an 
upregulated kinase in brains of AD patients. Pin1 binds GSK3β at pThr-330-Pro motif, suppressing 
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its kinase activity, leading to decreased toxic amyloid-beta peptide generation and increased APP 
turnover [45]. These data show the ability of Pin1 to regulate, directly or indirectly, the fate of APP 
and confirm its neuroprotective role in AD. 
5. Pin1 and HD 
HD is an adult-onset, inherited neurodegenerative disorder that results from expanded CAG 
repeats in exon 1 of the coding gene (Htt). The hallmark symptoms of HD can include motor and 
cognitive impairments which are caused by gradual loss of neurons especially in the striatum. It is 
hypothesized that HD is caused by either a loss-of-function of the wild type protein Htt or a toxic 
gain-of-function of mutant Htt. Indeed, mutant Htt leads to the formation of intracellular aggregates 
in the central nervous system, as well as in peripheral tissues [46, 47]. These inclusions trigger toxic 
cellular events such as mitochondrial dysfunction, reactive oxygen species generation, DNA damage, 
and inhibition of neural-specific transcription [48].  
The p53 tumor suppressor gene mediates Htt-induced toxicity in in vitro and in vivo models of 
HD [49], and the underlying mechanism is being fully investigated. In fact, p53 plays a key role in 
the regulation of apoptosis in HD, in addition to its role in other neurodegenerative diseases, and its 
anti-apoptotic activity requires Pin1 involvement [50, 51]. Specifically, mutant Htt induces the 
activation of a stress-signaling cascade involving ATM, HIPK2, and PKCdelta kinases, leading to 
p53 phosphorylation on the Ser-46 motif. This event triggers the isomerization of pSer-46-Pro-47 site 
by Pin1, allowing for the dissociation of p53 from the apoptosis inhibitor iASPP and the consequent 
induction of apoptotic target genes [8]. 
Besides this mechanism, Pin1 also regulates a transcription-independent apoptosis pathway 
which may contribute to neuronal death in HD. In this case, the prolyl-isomerization of pSer-46 
induces p53 monoubiquitination, its mitochondrial translocation, and direct apoptosis [52]. Moreover, 
the early activation of p53 is prevented by Pin1 genetic ablation in a mouse model of HD, suggesting 
the protective role of targeting Pin1 in mutant Htt-related neurodegeneration [8].  
6. Pin1 and PD 
PD is a chronic, progressive neurodegenerative disorder that mainly occurs in the population 
older than 60 years, but can appear in much younger people. PD is not only associated with an 
impairment of motor control, but also with non-motor symptoms such as cognitive deficits, 
neurobehavioral disorders, and autonomic dysfunction [53]. Currently, there is no cure for PD and 
only symptomatic pharmacological approaches to treat motor abnormalities are available. The 
appearance of these symptoms results from loss or degeneration of dopaminergic neurons in the 
midbrain and accumulation of neuronal inclusions, called Lewy bodies, in the surviving neurons of 
the substantia nigra [54]. 
Most α-syn in these inclusions is phosphorylated at Ser-129, suggesting the relevance of 
phosphorylation mechanisms in α-syn aggregation [6, 55, 56]. Phosphorylation can also indirectly 
influence α-syn aggregation, as shown by Ryo and colleagues. These authors showed that 
phosphorylation of synphilin-1, an α-syn-binding protein, allows the binding of Pin1 on its 
Ser-211-Pro and Ser-215-Pro motifs. This promotes synphilin-1-α-syn interaction and likely α-syn 
inclusions generation [57].  
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In addition, Pin1 has been detected in Lewy bodies of human PD brain tissues, linking it to the 
pathogenesis of the disease [57]. Moreover, a recent paper provided further details showing Pin1 
up-regulation in cell culture, animal models of PD and in human PD brains. It also showed the 
pro-apoptotic function of Pin1 in dopaminergic neurons [58].  
Interestingly, p53 dependent neuronal death has been reported also in in vitro and in vivo 
models of PD [59, 60], as well as increased p53 levels in PD human brains [61]. These results 
provide convincing evidence of the interplay between Pin1 and p53 in PD, but more efforts should 
be made to understand the exact mechanism underlying this interaction. In conclusion, Pin1 
signaling may represent a potential target for neuroprotection in PD. 
7. Pin1 and prion diseases 
Prion diseases, or transmissible spongiform encephalopathies (TSE), are a group of infectious, 
genetic or sporadic pathologies that affect nervous system of animals and humans [62,63]. Animal 
prion diseases include scrapie in sheep and goats, as well as bovine spongiform encephalopathy 
(BSE), known as “mad cow disease”. Human prion diseases are classified into Creutzfeldt-Jakob 
Disease (CJD), variant CJD, Gerstmann-Sträussler-Scheinker syndrome (GSS), fatal familial 
insomnia, and kuru. Prion disorders are characterized by the accumulation of prion protein 
aggregates resistant to proteinase K digestion in the brain. These insoluble inclusions derive from the 
conformational transition of the normal, soluble, cellular prion protein (PrPC),which are rich in 
α-helical structures, into scrapie prion protein (PrPSc) or prions, predominantly composed of 
β-sheet-structures [64, 65]. Although PrPC conversion is a key event in the pathogenesis of prion 
diseases, the molecular mechanism involved has not been definitely clarified. Since, under normal 
conditions, the spontaneous conversion of PrPC into PrPSc is prevented by the high-energy barrier 
between the two isoforms, many factors have been proposed to induce this process [66]. These 
include pathogenic mutations and several cofactors, such as glycosaminoglycans, lipids, nucleic 
acids, metals, and post-translational modifications. The latter include glycosylation, oxidation, 
advanced glycation end-product modification, and phosphorylation [66]. Several kinases 
phosphorylate PrPC, including Fyn, casein kinase II, and Cdk5 [67]. Interestingly, neuronal Cdk5 
phosphorylates PrPC at Ser-43, inducing protein conformational change that leads to the formation of 
insoluble, proteinase K-resistant aggregates in vitro and also in PrPSc -infected mice brains. Thus, 
Cdk5-dependent phosphorylation directly determines prion protein conversion [12]. 
Accordingly, Cdk5 levels were observed to increase in PrPSc -infected animal brains [68], as 
was pSer-43 PrPC in the cerebral spinal fluid of sporadic CJD patients [69]. Recently, pSer-43 was 
shown to cause or exacerbate PrPC mutant conversion into amyloid structure [70], confirming the 
importance of phosphorylation in PrPC conversion and also in the presence of PrPC -related familial 
mutations. Ser-43 motif is one of two Ser-Pro phosphorylation sites in PrPC and is located in the N 
terminus of the mature protein at amino acids Ser-43-Pro-44. The other site is in the glycosyl 
phosphatidylinositol-anchor signal peptide at Ser-237-Pro-238 [12]. Moreover, the N-terminal 
domain of the prion protein seems to be involved in PrPC function, in addition to PrPSc formation. 
Indeed, this domain was shown to direct prion protein oligomeric association [71] during in vivo and 
in vitro aggregation [72, 73]. 
In this context, it could be interesting to investigate the possible role of Pin1 in regulating the 
conversion of PrPC into PrPSc. It can be envisioned that Pin1 may catalyze the conformational change 
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of pSer-43 at the N-terminal domain, influencing PrPC isomerization and contributing to the 
physiological function of PrPC. Pin1 dysfunction could alter this process leading to increased levels 
of pSer-43 and, consequently, to PrPSc generation. This scenario would resemble Pin1 involvement in 
tau or APP isomerization, and could promote deep investigation of the potential interplay between 
Pin1 and PrPC. In fact, as for AD, HD, and PD, prion disorders could also have a link with the 
dysregulation of Pin1 activity that could be confirmed or refuted by measuring Pin1 levels in patients 
affected by prion diseases.  
8. Conclusions 
In this review we discussed the state of the art concerning the role of Pin1 in neurodegenerative 
disorders. Much evidence suggests that Pin1 regulation could represent a potential therapeutic target 
for AD, HD, and PD. The current therapeutic approach for AD consists of targeting the pathogenic 
cis isoform of tau by conformation specific antibodies [38]. Furthermore, the reduction of Pin1 
oxidation may be a promising field to investigate in AD. In the case of PD, several inhibitors have 
been found to reduce MPP+-induced Pin1 upregulation in cellular models of PD and notably, juglone 
treatment was able to induce neuroprotection against dopaminergic degeneration in a mouse model 
of PD [58]. Thereby, developing and testing pharmacological compounds to inhibit Pin1 may be an 
attractive therapeutic strategy in PD, as well as in HD. In fact, some evidence showed that 
small-molecule inhibitors of Pin1, such as PiB, protect from Htt-induced apoptosis [74]. 
Despite mechanisms underlying Pin1 involvement in these pathologies are not always yet clear, 
tight regulation of Pin1 could be useful to restore disease-related protein function. Indeed, Pin1 
inhibition determines opposite effects in neurodegenerative disorders: on the one hand it leads to a 
reduction of inclusions in PD and decreased neuronal apoptosis in HD while, while on the other hand, 
it seems to exacerbate AD pathology. The discrepancy of Pin1 function in neurodegenerative 
disorders may be ascribed to its wide range of phosphorylated substrates and, likely, even to the 
specific phosphorylation motifs within the same substrates (Figure 1), depending on individual 
Ser/Thr-Pro site conformation after phosphorylation [2]. 
 
Figure 1. Pin 1 involvement in neurodegenerative diseases: potential Pin 1-binding targets. 
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Finally, the effect of Pin1 inhibition in prion diseases is yet unknown, but recent evidence 
promotes an investigation of the role of the PPIase in this pathology. It is intriguing to consider that 
the enzymatically driven conformational change of PrPC to PrPSc may regulate prion conversion and 
accumulation. Thus, endeavoring to understand whether Pin1 is involved in PrPSc formation could 
eventually constitute Pin1 as a therapeutic target for prion diseases as hypothesized for other 
neurodegenerative diseases. 
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